Axsome Therapeutics

OverviewSuggest Edit

Axsome Therapeutics is a clinical-stage biopharmaceutical company that develops therapies for the management of central nervous system (CNS) disorders. The Company works on product candidates for the treatment of resistant depression and Alzheimer's disease agitation, complex regional pain syndrome, knee osteoarthritis related to bone marrow lesions, and chronic low back pain related to Modic changes. It is also developing a preclinical product candidate for CNS disorders, including chronic pain.

TypePublic
Founded2012
HQNew York, US
Websiteaxsome.com

Latest Updates

Employees (est.) (Nov 2019)41(+11%)
Job Openings5
Share Price (Sept 2020)$81.3 (+4%)
Cybersecurity ratingAMore

Key People/Management at Axsome Therapeutics

Herriot Tabuteau

Herriot Tabuteau

CEO
John Golubieski

John Golubieski

CFO
Robert Niecestro

Robert Niecestro

VP, Head of Regulatory Affairs
Show more

Axsome Therapeutics Office Locations

Axsome Therapeutics has an office in New York
New York, US (HQ)
200 Broadway 3rd Floor
Show all (1)

Axsome Therapeutics Financials and Metrics

Axsome Therapeutics Revenue

USD

Net income (Q2, 2020)

(18.3m)

EBIT (Q2, 2020)

(17.8m)

Market capitalization (22-Sept-2020)

3.0b

Closing stock price (22-Sept-2020)

81.3

Cash (30-Jun-2020)

190.7m

EV

2.9b
Axsome Therapeutics's current market capitalization is $3 b.
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019

General and administrative expense

6.3m7.2m9.4m13.6m

R&D expense

21.2m20.0m23.5m53.6m

Operating expense total

27.5m27.2m32.8m67.2m

EBIT

(27.5m)(27.2m)(32.8m)(67.2m)
Quarterly
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

General and administrative expense

1.4m1.5m1.6m1.7m1.7m1.8m2.4m2.4m2.2m2.8m2.4m3.1m5.0m7.2m

R&D expense

4.5m5.3m5.6m6.0m5.0m4.5m4.8m5.6m6.0m7.6m11.0m15.8m27.5m10.5m

Operating expense total

5.9m6.8m7.2m7.7m6.8m6.3m7.2m8.0m8.2m10.4m13.4m18.9m32.5m17.8m

EBIT

(5.9m)(6.8m)(7.2m)(7.7m)(6.8m)(6.3m)(7.2m)(8.0m)(8.2m)(10.4m)(13.4m)(18.9m)(32.5m)(17.8m)
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019

Cash

36.6m34.0m14.0m220.0m

Prepaid Expenses

1.3m1.2m413.1k

Inventories

2.6m

Current Assets

38.0m35.3m15.2m220.4m
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(27.2m)(28.9m)(31.0m)(68.3m)

Depreciation and Amortization

20.5k42.6k48.9k37.3k

Inventories

(383.9k)

Accounts Payable

2.2m(645.7k)251.8k7.3m
USDQ1, 2016

Financial Leverage

1.1 x
Show all financial metrics

Axsome Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

97/100

SecurityScorecard logo

Axsome Therapeutics Online and Social Media Presence

Embed Graph

Axsome Therapeutics News and Updates

Axsome Therapeutics Announces AXS-07 Phase 3 Migraine Trial Results Selected by the American Academy of Neurology Science Committee as Featured Presentation

Data from MOMENTUM Phase 3 trial to be presented at the 2020 AAN Science Highlights Platform

Axsome Therapeutics Presents New Data from GEMINI Phase 3 Trial with AXS-05 Demonstrating Rapid and Significant Improvements in Patient-Reported Outcomes in Major Depressive Disorder

Rapid, durable, and statistically significant improvement demonstrated in patient-reported depressive symptoms, as measured by the QIDS-SR-16 total score compared to placebo (p=0.001)

Axsome Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business Update

Two NDA submissions, for AXS-05 in MDD and for AXS-07 in migraine, on track for 4Q 2020

Axsome Therapeutics to Report Second Quarter 2020 Financial Results on August 10, 2020

Axsome to host conference call and webcast on Monday, August 10, 2020 at 8:00 AM Eastern Time

Thinking about trading options or stock in Axsome Therapeutics, Virgin Galactic, Dynavax Technologies, Big Lots, or Walt Disney?

NEW YORK, June 26, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AXSM, SPCE, DVAX, BIG, and DIS. Click a link below then choose between in-depth options trade idea report or a stock score report. Options Report – Ideal trade ideas on up to seven different...
Show more

Axsome Therapeutics Blogs

Axsome Therapeutics Receives FDA Breakthrough Therapy Designation for AXS-12 for the Treatment of Narcolepsy

Axsome Therapeutics Receives FDA Breakthrough Therapy Designation for AXS-12 for the Treatment of Narcolepsy Content Import Wed, 08/05/2020 - 07:03 Axsome Therapeutics Receives FDA Breakthrough Therapy Designation for AXS-12 for the Treatment of Narcolepsy August 05, 2020 …

Axsome Therapeutics Receives FDA Breakthrough Therapy Designation for AXS-05 for the Treatment of Alzheimer’s Disease Agitation

Designation offers potential for expedited development and review Axsome now granted two Breakthrough Therapy designations for AXS-05 for separate CNS indications NEW YORK , June 26, 2020 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel

Axsome Therapeutics Presents Data from GEMINI Phase 3 Trial of AXS-05 in Major Depressive Disorder at the 2020 American Society for Clinical Psychopharmacology Annual Meeting

NEW YORK , May 29, 2020 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that data from the GEMINI Phase 3 trial of AXS-05 in major depressive disorder

Axsome Therapeutics to Host 2020 Annual Meeting of Stockholders Virtually

Axsome Therapeutics to Host 2020 Annual Meeting of Stockholders Virtually Content Import Tue, 05/26/2020 - 07:01 Axsome Therapeutics to Host 2020 Annual Meeting of Stockholders Virtually May 26, 2020 This release is a backfill from a News Wire G…

Axsome Therapeutics Reports First Quarter 2020 Financial Results and Provides Business Update

Clinical successes highlight Axsome’s accelerated evolution into a leading CNS company Positive pivotal Phase 2/3 results for AXS-05 in Alzheimer’s disease agitation further deepen innovative pipeline Positive efficacy results in 5 significant CNS indications with 4 candidates advance broad

Q1 2020 Axsome Therapeutics, Inc. Earnings Conference Call

Q1 2020 Axsome Therapeutics, Inc. Earnings Conference Call Michael.Fuccio… Thu, 04/30/2020 - 09:01 Q1 2020 Axsome Therapeutics, Inc. Earnings Conference Call Display "add to calendar" true Event Type Earnings Conference Call Ev…
Show more

Axsome Therapeutics Frequently Asked Questions

  • When was Axsome Therapeutics founded?

    Axsome Therapeutics was founded in 2012.

  • Who are Axsome Therapeutics key executives?

    Axsome Therapeutics's key executives are Herriot Tabuteau, John Golubieski and Robert Niecestro.

  • How many employees does Axsome Therapeutics have?

    Axsome Therapeutics has 41 employees.

  • Who are Axsome Therapeutics competitors?

    Competitors of Axsome Therapeutics include Y-mAbs Therapeutics, Gilead Sciences and Prevail Therapeutics.

  • Where is Axsome Therapeutics headquarters?

    Axsome Therapeutics headquarters is located at 200 Broadway 3rd Floor, New York.

  • Where are Axsome Therapeutics offices?

    Axsome Therapeutics has an office in New York.

  • How many offices does Axsome Therapeutics have?

    Axsome Therapeutics has 1 office.